- Eli Lilly (NYSE:LLY) has become the first healthcare firm to reach a $1 trillion market valuation, primarily driven by its leading position in the weight loss drug market.
- The company demonstrates strong financial performance, with revenue growth of 55.5% year-over-year and a raised full-year revenue guidance, despite concerns over pricing and international profit margins.
- The competitive landscape in the obesity drug market is intensifying, with major players like Pfizer (NYSE:PFE) and Novo Nordisk (NYSE:NVO) actively investing to challenge Eli Lilly’s market share.
Eli Lilly is a major pharmaceutical company that recently became the first healthcare firm to reach a $1 trillion market valuation. This achievement is driven by its leading position in the weight loss drug market. The company develops and sells a range of pharmaceutical products globally, with a strong focus on innovative treatments.
On June 22, 2026, analyst firm Cantor Fitzgerald confirmed its “Overweight” rating for Eli Lilly, with the stock at $1098.13. This positive view is supported by strong financial performance. In a recent quarter, the company’s revenue grew 55.5% year-over-year to $19.80 billion, as highlighted by 247wallst.com.
A key driver of this growth is the drug Mounjaro, which contributed $8.66 billion to the quarterly revenue. As noted by The Motley Fool, the company’s product Zepbound is also seeing rapid sales. This success led management to raise its full-year revenue guidance to a range between $82 billion and $85 billion.
Despite strong results, Eli Lilly’s stock shows a modest year-to-date increase of just 2.57%. Concerns exist over pricing, as realized prices fell 13% in the first quarter. This drop was partly due to Mounjaro’s inclusion on China’s National Reimbursement Drug List, which reduces international profit margins for the company.
The company operates in a competitive market. As highlighted by Zacks, Pfizer (NYSE:PFE) aims to challenge Eli Lilly and Novo Nordisk (NYSE:NVO) in the obesity space, which is projected to reach nearly $120 billion by 2035. Pfizer is investing heavily in new treatments, planning over 20 obesity studies in 2026 to gain market share.
